Pharmafile Logo

News and Press Releases

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

19 March 2025 -- Hong Kong, Shanghai & New Jersey, US -- HUTCHMED (China) Limited and Innovent Biologics, Inc, today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies

Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO platform combining best-in-class technology with industry-leading development and manufacturing capabilities 18 March 2025 -- Pennsylvania, US and...

Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 18, 2025

Ori Biotech
Media@OriBiotech.com
CIC Philadelphia 3675 Market St, Suite 200 Philadelphia, PA 19204

SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers 17 March 2025 -- Cambridge,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: March 17, 2025

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

Advarra Unveils Oncology Research Pulse

Content-driven program brings together clinical trial stakeholders to foster knowledge sharing and collaboration in cancer research 12 March 2025 -- Maryland, US -- Advarra, the market leader in regulatory review...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 12, 2025

Advarra
6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Fondazione Telethon Submits US Biological License Application for Etuvetidigene Autotemcel Gene Therapy for the Treatment of Wiskott-Aldrich Sydrome

11 March 2025 -- Milan, Italy -- Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, announced that it has submitted the Biologics License Application (BLA) for the...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 11, 2025

Fondazione Telethon
info@telethon.it
Via Poerio 14 - 20129 Milano

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Combination of complete skin clearance data and favourable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (Pso) treated with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

10 March 2025 -- London, UK and New York, US -- OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Innovaderm Research Rebrands as Indero, a dual-focus CRO 

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero
3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe

FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH) ODD status may expedite drug candidate development and approvals BIOX-101 interim Phase 2a data in ICH imminent. 5...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 5, 2025

Bioxodes
info@bioxodes.com
Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union

4 March 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, announced that its eConsent and eCOA solutions have been approved for use in two...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Centauri
info@centauritherapeutics.com
Discovery Park, Sandwich CT13 9ND

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

4 March 2025 -- Pennsylvania, US and Dublin, Ireland -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc, a global healthcare intelligence and clinical research...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025

ICON
South County Business Park, Leopardstown, Dublin 18, Ireland

Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies

Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritis Pivotal clinical trial in osteoarthritis patients on track to start in 2025. 4 March 2025 -- Liege, Belgium -- Allegro...

Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: March 4, 2025

Allegro Bio
info@allegro.bio
Boulevard Patience et Beaujonc 3 4000 Liège Belgium

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

25 February 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom